Shin Nippon Biomedical Laboratories
Shin Nippon Biomedical Laboratories, often referred to as SNBL, is a prominent player in the global preclinical and clinical research industry. Headquartered in Japan, the company operates extensively across Asia, Europe, and North America, providing comprehensive services in drug development and safety assessment. Founded in 1997, SNBL has achieved significant milestones, including the establishment of state-of-the-art facilities that adhere to international regulatory standards. The company specialises in a range of core services, including toxicology, pharmacokinetics, and bioanalytical testing, distinguished by its commitment to scientific excellence and innovation. With a strong market position, SNBL is recognised for its robust partnerships with pharmaceutical and biotechnology firms, contributing to the advancement of medical research and the development of new therapies.
DitchCarbon Score
How does Shin Nippon Biomedical Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shin Nippon Biomedical Laboratories's score of 34 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shin Nippon Biomedical Laboratories's reported carbon emissions
In 2023, Shin Nippon Biomedical Laboratories (SNBL) reported total carbon emissions of approximately 14,623,000 kg CO2e, comprising 5,389,000 kg CO2e from Scope 1, 9,234,000 kg CO2e from Scope 2, and 312,000 kg CO2e from Scope 3 emissions. This reflects a continued commitment to monitoring and managing their carbon footprint within the pharmaceuticals, biotechnology, and life sciences sector. Over the years, SNBL has demonstrated a proactive approach to emissions reduction. In 2022, their total emissions were about 11,561,000 kg CO2e, indicating a significant increase in emissions in 2023. However, the company has set near-term reduction targets, although specific numerical goals have not been disclosed. As of September 2023, SNBL is committed to reducing its emissions but has not yet pledged to achieve net-zero emissions. The company has consistently reported emissions across all three scopes, with a notable focus on Scope 2 emissions, which are primarily associated with energy consumption. Their emissions per employee have also been tracked, with figures around 22,000 kg CO2e in 2019 and 21,000 kg CO2e in 2020, highlighting their efforts to improve efficiency. Overall, while SNBL has made strides in understanding and reporting its carbon emissions, the path forward will require clear targets and strategies to effectively reduce its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 3,176,000 | - | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 7,630,000 | - | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 246,000 | - | - | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shin Nippon Biomedical Laboratories is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
